Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling

• DOI: 10.1096/fj.201500155r
• Publication Date: 2016-04-28T16:42:59Z
• Authors: Tarec K. Elajami; Romain A. Colas; Jesmond Dalli; Nan Chiang; Charles N. Serhan; Francine K. Welty
• Keywords: Male; 0301 basic medicine; Aspirin; Docosahexaenoic Acids; Coronary Disease; Middle Aged; Lipid Metabolism; Lipoxins; Drug Combinations; 03 medical and health sciences; Eicosapentaenoic Acid; Gene Expression Regulation; Fatty Acids, Omega-3; Humans; Female; Biomarkers; Platelet Aggregation Inhibitors; Aged

Inflammation in arterial walls leads to coronary artery disease (CAD). Because specialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and protectins) stimulate resolution of inflammation animal models, we tested whether n-3 fatty acids impact SPM profiles patients with CAD promote clot remodeling. Six stable were randomly assigned either treatment daily 3.36 g Lovaza for 1 yr or without. Targeted mediator-metabololipidomics showed that both groups had absence resolvin D1 (RvD1), RvD2, RvD3, RvD5 E1-all which are present healthy patients. Those not taking an aspirin-triggered D3 (AT-RvD3) lipoxin B4 (AT-LXB4). restored AT-RvD3 AT-LXB4 gave levels RvD6 protectin (AT-PD1) twice as high (resolvin E2 ∼5 fold) well lower prostaglandins. Principal component analysis indicated positive relationships who receiving increased AT-RvD3, RvD6, AT-PD1, SPMs identified Lovaza-treated enhanced ∼50% at nM macrophage uptake blood clots. These results indicate have and/or specific Lovaza; these phagocytosis Together, they suggest low vascular may enable progression chronic predisposing atherosclerosis thrombosis.-Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. Welty, F. K. Specialized their potential